PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 394 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Triple Negative Breast Cancer May Not Be Categorized As ‘Breast’ Cancer... February 4, 2020 Tailored Radiation to Treat Brain Metastases Reduces Impact on Cognitive Function November 26, 2018 Attorney Donates $30K In Gift Cards So Parents Can Purchase Gifts... December 17, 2021 Selumetinib Approved by FDA to Treat Children with NF1 April 14, 2020 Load more HOT NEWS Έγκριση νέας επικουρικής θεραπείας για τον θετικά πρώιμο καρκίνο του μαστού Surveillance and Early Cancer Detection are Associated with Improved Survival in... KRASG12D-Mutated NSCLC is Subtype with Distinct Co-mutations, a Colder Immune Microenvironment,... Characterisation of KRAS, Including KRAS G12C, Mutations in Gastrointestinal and Metastatic...
